Expression of vimentin, TPI and MAT2A in human dermal microvascular endothelial cells during angiogenesis in vitro.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
10
2021
accepted:
27
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
3
5
2022
Statut:
epublish
Résumé
In vitro assays of angiogenesis face immense problems considering their reproducibility based on the inhomogeneous characters of endothelial cells (ECs). It is necessary to detect influencing factors, which affect the angiogenic potency of ECs. This study aimed to analyse expression profiles of vimentin (VIM), triosephosphate isomerase (TPI) and adenosylmethionine synthetase isoform type-2 (MAT2A) during the whole angiogenic cascade in vitro. Furthermore, the impact of knocking down vimentin (VIM) on angiogenesis in vitro was evaluated, while monitoring TPI and MAT2A expression. A long-term cultivation and angiogenic stimulation of human dermal microvascular ECs was performed. Cells were characterized via VEGFR-1 and VEGFR-2 expression and a shRNA-mediated knockdown of VIM was performed. The process of angiogenesis in vitro was quantified via morphological staging and mRNA-and protein-levels of all proteins were analysed. While native cells ran through the angiogenic cascade chronologically, knockdown cells only entered beginning stages of angiogenesis and died eventually. Cell cultures showing a higher VEGFR-1 expression survived exclusively and displayed an upregulation of MAT2A and TPI expression. Native cells highly expressed VIM in early stages, MAT2A mainly in the beginning and TPI during the course of angiogenesis in vitro. VIM knockdown led to a deceleration of angiogenesis in vitro and knockdown cells displayed expressional changes in TPI and MAT2A. Cell populations with a higher number of stalk cells emerged as being more stable against manipulations and native expression profiles provided an indication of VIM and MAT2A being relevant predominantly in beginning stages and TPI during the whole angiogenic cascade in vitro.
Identifiants
pubmed: 35482724
doi: 10.1371/journal.pone.0266774
pii: PONE-D-21-34603
pmc: PMC9049311
doi:
Substances chimiques
Vimentin
0
MAT2A protein, human
EC 2.5.1.6
Methionine Adenosyltransferase
EC 2.5.1.6
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Triose-Phosphate Isomerase
EC 5.3.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266774Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Blood. 2006 Oct 1;108(7):2339-48
pubmed: 16794251
Physiol Rev. 2004 Jul;84(3):869-901
pubmed: 15269339
Biomed Mater. 2013 Apr;8(2):025002
pubmed: 23343569
J Cell Sci. 2003 Dec 15;116(Pt 24):4977-84
pubmed: 14625391
Iran J Basic Med Sci. 2012 Nov;15(6):1110-26
pubmed: 23653839
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3225-30
pubmed: 17296941
Biochim Biophys Acta. 2009 Dec;1792(12):1168-74
pubmed: 19786097
J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S73-7
pubmed: 18336669
Biol Pharm Bull. 2007 Feb;30(2):247-53
pubmed: 17268060
Cell Mol Life Sci. 2010 Dec;67(23):3961-82
pubmed: 20694739
Stem Cell Res Ther. 2017 Aug 14;8(1):184
pubmed: 28807010
ALTEX. 2004;21(4):227-44
pubmed: 15586254
Polymers (Basel). 2017 Nov 04;9(11):
pubmed: 30965879
APMIS. 2007 Jan;115(1):30-46
pubmed: 17223849
Saudi Pharm J. 2015 Jul;23(3):223-9
pubmed: 26106269
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4574-E4581
pubmed: 28533359
Arch Biochem Biophys. 2004 Mar 15;423(2):332-42
pubmed: 15001397
Microcirculation. 2014 May;21(4):333-44
pubmed: 24387004
PLoS One. 2014 Jun 13;9(6):e99678
pubmed: 24926893
J Cell Biol. 2003 Jun 23;161(6):1163-77
pubmed: 12810700
Sci Rep. 2019 Oct 21;9(1):15022
pubmed: 31636306
Biochem J. 2013 May 15;452(1):27-36
pubmed: 23425511
J Am Chem Soc. 2017 Oct 4;139(39):13754-13760
pubmed: 28880543
Methods Mol Biol. 2016;1464:185-191
pubmed: 27858367
Sci Rep. 2019 Aug 30;9(1):12608
pubmed: 31471554
Exp Cell Res. 2010 Jan 15;316(2):172-80
pubmed: 19715692
Science. 2002 Feb 1;295(5556):868-72
pubmed: 11786607
J Neurooncol. 2000 Oct-Nov;50(1-2):1-15
pubmed: 11245270
Int J Mol Sci. 2020 Mar 28;21(7):
pubmed: 32231163
PLoS Biol. 2007 Dec;5(12):e321
pubmed: 18052609
PLoS One. 2015 Jan 24;10(1):e0115853
pubmed: 25617624
Bioessays. 2020 Nov;42(11):e2000078
pubmed: 32893352
Clin Hemorheol Microcirc. 2011;48(1):15-27
pubmed: 21876231
Clin Hemorheol Microcirc. 2010;46(2-3):189-202
pubmed: 21135494
Bioessays. 2016 Mar;38(3):232-43
pubmed: 26763143
Mol Biol Rep. 2021 Jan;48(1):941-950
pubmed: 33393005
EMBO J. 2021 Mar 1;40(5):e106700
pubmed: 33439509
Dev Biol. 2012 Dec 15;372(2):157-65
pubmed: 23031691
Cells. 2018 Sep 21;7(10):
pubmed: 30248895
Biomedicines. 2019 May 16;7(2):
pubmed: 31100863
J Nanobiotechnology. 2021 Jan 4;19(1):1
pubmed: 33397416
Am J Physiol Cell Physiol. 2010 Aug;299(2):C363-73
pubmed: 20427712
Gene Ther. 2012 Nov;19(11):1058-64
pubmed: 22113311
Clin Hemorheol Microcirc. 2013 Jan 1;55(2):255-69
pubmed: 23089887
Angiogenesis. 2018 Aug;21(3):425-532
pubmed: 29766399
Nature. 1997 Apr 17;386(6626):671-4
pubmed: 9109485
Cancer Metastasis Rev. 2010 Dec;29(4):655-76
pubmed: 20821252